Follow The Filings

URGN

Earnings company data as of 8:02 PM ET 10/22

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 5 Nov EPS 0.38 — —
Rev — — —

Insider trades

Open-market buys and sales by URGN's executives, directors and 10% owners in the last 12 months, from their Form 4s

All URGN insider trades
  • None no insider bought on the open market
  • $2.9M sold by 1 insider outside a trading plan
  • $1.3M sold by 1 insider under 10b5-1 plans
  1. Mark Schoenberg Chief Medical Officer
    Sale
    $2.9M 60,677 shares at $47.05 51% of stake
    Traded Aug 20 Filed Aug 24
  2. Mark Schoenberg Chief Medical Officer
    Planned sale
    $400K 10,000 shares at $40.00 7.7% of stake
    Traded Jul 9 Filed Jul 10
  3. Mark Schoenberg Chief Medical Officer
    Planned sale
    $350K 10,000 shares at $35.01 7.2% of stake
    Traded Jun 22 Filed Jun 24
  4. Mark Schoenberg Chief Medical Officer
    Planned sale
    $300K 10,000 shares at $30.00 6.9% of stake
    Traded May 8 Filed May 11
  5. Mark Schoenberg Chief Medical Officer
    Planned sale
    $250K 10,000 shares at $25.00 6.7% of stake
    Traded Nov 19, 2025 Filed Nov 20, 2025

Also filed in the last 12 months, not counted as buying or selling: 17 option exercises and 10 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 16 shown.

Filed Form Detail Links
8-K 8.01
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q FORM 10-Q
8-K 3.03,5.02,5.07,9.01
8-K 8.01
SCHEDULE 13G —
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q FORM 10-Q
DEF 14A FORM DEF 14A
SCHEDULE 13G —
8-K 1.01,2.03
8-K 2.02,9.01
10-K FORM 10-K
SCHEDULE 13G/A —

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.